Objective To explore the influence of the combination of Shuxuetong (SXT) and aspirin on coagulation and fibrinolytic system of rats. Methods Suture method was applied to establish focal cerebral ischemia-reperfusion injury models in rats. A total of 50 SD rats were randomly divided into sham group, middle cerebral artery occlusion/reperfusion (MCAO/R) group, aspirin (10 mg/kg) group, SXT (0.6 mL/kg) group, and SXT (0.6 mg/kg) + aspirin (10 mg/kg) group. The neurological deficits were assessed according to Longa's grade 5 scoring method. The cerebral edema was detected by measuring the content of water in brain tissue. The volume of cerebral infarction was observed by 2,3,5-Triphenyltetrazolium chloride (TTC) staining. Blood plasma was collected by abdominal aortic method to test maximum platelet aggregation rate and four blood coagulation. CD61, CD62p, 6-keto prostaglandin F1α (6-keto-PGF1α), antithrombin III (AT-III), D-dimer, plasminogen activator inhibitor-1 (PAI-1), tissue factor (TF), tissue plasminogen activator (t-PA), platelet thromboxane B2 (TXB2), and von Willebrand factor (vWF) content in rat plasma were detected by ELISA. Results SXT combined with aspirin could improve the neurological deficits, alleviate cerebral edema, and decrease the cerebral infarct value. Compared with the sham operation group, fibrinogen (FIB), 6-PGF1α, AT-III, and t-PA in model group were significantly decreased; Compared with the model group, the above-mentioned indexes in SXT and aspirin treatment group were significantly increased. The prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), D-dimer, PAI-1, TF, TXB2, and vWF of the model group were significantly increased; the above-mentioned indexes in blood SXT + aspirin treated group were significantly decreased. There was a significant difference between the combined group and SXT group. The maximum concentration of plateletsin aspirin treated rats was significantly decreased, however, MPAR was reversed in SXT + aspirin treated group. Conclusion SXT combined with aspirin can effectively inhibit platelet activation, regulate the maximum concentration of platelets, and improve coagulation function and fibrinolysis system.
